+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030- Product Image
Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030- Product Image
New

Antidiabetics Market Size, Share & Trends Analysis Report by Drug Class (GLP-1 Receptor Agonists, Insulin), Diabetes Type (Type 1, 2), Route of Administration (Oral, Intravenous), Distribution Channel, Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5983030
Description Jump to:
The Antidiabetics Market was valued at USD 91.34 Billion in 2024, and is projected to reach USD 168.55 Billion by 2030, rising at a CAGR of 10.75%. The growing prevalence of diabetes is the primary driver of this market. Growth in irregular dietary habits and obesity is also expected to boost product demand by triggering incidence rates of target diseases. Future commercialization of products currently in the pipeline and the presence of large untapped opportunities in the emerging Asia-Pacific and Latin American markets is expected to fuel future market growth.

Insulin was the most revenue-generating segment and its market was valued at over USD 20.0 billion in 2013. Insulin is also one of the most lucrative segments of this market. The introduction of new products exhibiting higher efficacy coupled with the presence of favorable government initiatives are some factors attributing to its market attractiveness.

Antidiabetics Market Report Highlights

  • The rapid uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina, and Onglyza on account of their once-daily dosage regimens and safety profiles catalyzed the growth of this market.
  • North America was the most mature antidiabetics market in 2024 accounting for over 41.48% of the market High market penetration of insulin and other antidiabetics and the presence of sophisticated reimbursement framework are expected to drive regional market growth.
  • Asia-Pacific is expected to present manufacturers with lucrative future growth opportunities. Large presence of unmet patient needs and rapidly improving healthcare infrastructure are some factors expected to drive market growth in the region. The market is also expected to be driven by the introduction of cheaper products made available by local manufacturers.
  • Some key market players of antidiabetics include AstraZeneca plc, Bayer AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim, Bristol-Myers Squibb Company, Merck & Co. Inc, Johnson & Johnson Services Inc. and Pfizer.
  • The market is oligopolistic in nature with few players accounting for over 70% of the market. Extensive R&D investments aimed at new product development and entering new markets via government contracts are the key sustainability strategies adopted by these organizations.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Diabetes Type
1.2.3. Distribution Channel
1.2.4. Route of Administration
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information or Data Analysis:
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Rising Diabetes Prevalence
3.3.2. Advancements in Research and Technology
3.3.3. Increasing Awareness and Early Intervention
3.4. Market Restraint Analysis
3.4.1. High Development Costs
3.4.2. Side Effects and Safety Concerns
3.5. Industry Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL Analysis
3.6. Pricing Analysis
3.7. Pipeline Analysis
Chapter 4. Antidiabetics Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2030
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.4. Insulin
4.4.1. Insulin Market, 2018-2030 (USD Million)
4.4.1.1. Insulin Market, by Type
4.4.1.1.1. Long-acting insulin
4.4.1.1.1.1. Long-acting insulin market, 2018-2030 (USD Million)
4.4.1.1.2. Premix insulin
4.4.1.1.2.1. Premix insulin market, 2018-2030 (USD Million)
4.4.1.1.3. Fast-acting insulin
4.4.1.1.3.1. Fast-acting insulin market, 2018-2030 (USD Million)
4.4.1.1.4. Human insulin
4.4.1.1.4.1. Human insulin market, 2018-2030 (USD Million)
4.5. GLP-1 Receptor Agonists
4.5.1. GLP-1 Receptor Agonists Market, 2018-2030 (USD Million)
4.6. DPP- 4 Inhibitors
4.6.1. DPP- 4 Inhibitors Market, 2018-2030 (USD Million)
4.7. SGLT2 Inhibitors
4.7.1. SGLT2 Inhibitors Market, 2018-2030 (USD Million)
4.8. DPP-4 Inhibitors
4.8.1. DPP- 4 Inhibitors Market, 2018-2030 (USD Million)
4.9. Others
4.9.1. Others Market, 2018-2030 (USD Million)
Chapter 5. Antidiabetics Market: Diabetes Type Business Analysis
5.1. Diabetes Type Market Share, 2024 & 2030
5.2. Diabetes Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Diabetes Type , 2018 to 2030 (USD Million)
5.4. Type 1
5.4.1. Type 1 Market, 2018-2030 (USD Million)
5.5. Type 2
5.5.1. Type 2 Market, 2018-2030 (USD Million)
Chapter 6. Antidiabetics Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Oral
6.4.1. Oral Market, 2018-2030 (USD Million)
6.5. Subcutaneous
6.5.1. Subcutaneous Market, 2018-2030 (USD Million)
6.6. Intravenous
6.6.1. Intravenous Market, 2018-2030 (USD Million)
Chapter 7. Antidiabetics Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Online Pharmacies
7.4.1. Online Pharmacies Market, 2018-2030 (USD Million)
7.5. Hospital Pharmacies
7.5.1. Hospital Pharmacies, Market, 2018-2030 (USD Million)
7.6. Retail Pharmacies
7.6.1. Retail Pharmacies Market, 2018-2030 (USD Million)
Chapter 8. Antidiabetics Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2024 & 2030
8.2. Regional Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.4. North America
8.4.1. North America Antidiabetics Market Estimates and Forecasts, by Country, 2018-2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Target Disease Prevalence
8.4.2.3. Regulatory Framework
8.4.2.4. Reimbursement Framework
8.4.2.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Target Disease Prevalence
8.4.3.3. Regulatory Framework
8.4.3.4. Reimbursement Framework
8.4.3.5. U.S. Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Target Disease Prevalence
8.4.4.3. Regulatory Framework
8.4.4.4. Reimbursement Framework
8.4.4.5. Mexico Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5. Europe
8.5.1. Europe Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Target Disease Prevalence
8.5.2.3. Regulatory Framework
8.5.2.4. Reimbursement Framework
8.5.2.5. Uk Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Target Disease Prevalence
8.5.3.3. Regulatory Framework
8.5.3.4. Reimbursement Framework
8.5.3.5. Germany Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Target Disease Prevalence
8.5.4.3. Regulatory Framework
8.5.4.4. Reimbursement Framework
8.5.4.5. France Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Target Disease Prevalence
8.5.5.3. Regulatory Framework
8.5.5.4. Reimbursement Framework
8.5.5.5. Italy Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Target Disease Prevalence
8.5.6.3. Regulatory Framework
8.5.6.4. Reimbursement Framework
8.5.6.5. Spain Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Target Disease Prevalence
8.5.7.3. Regulatory Framework
8.5.7.4. Reimbursement Framework
8.5.7.5. Denmark Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Target Disease Prevalence
8.5.8.3. Regulatory Framework
8.5.8.4. Reimbursement Framework
8.5.8.5. Sweden Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Target Disease Prevalence
8.5.9.3. Regulatory Framework
8.5.9.4. Reimbursement Framework
8.5.9.5. Norway Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6. Asia Pacific
8.6.1. Asia Pacific Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.2. Japan
8.6.2.1. Key Country Dynamics
8.6.2.2. Target Disease Prevalence
8.6.2.3. Regulatory Framework
8.6.2.4. Reimbursement Framework
8.6.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Target Disease Prevalence
8.6.3.3. Regulatory Framework
8.6.3.4. Reimbursement Framework
8.6.3.5. China Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Target Disease Prevalence
8.6.4.3. Regulatory Framework
8.6.4.4. Reimbursement Framework
8.6.4.5. India Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Target Disease Prevalence
8.6.5.3. Regulatory Framework
8.6.5.4. Reimbursement Framework
8.6.5.5. Australia Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Target Disease Prevalence
8.6.6.3. Regulatory Framework
8.6.6.4. Reimbursement Framework
8.6.6.5. South Korea Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Target Disease Prevalence
8.6.7.3. Regulatory Framework
8.6.7.4. Reimbursement Framework
8.6.7.5. Thailand Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7. Latin America
8.7.1. Latin America Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Target Disease Prevalence
8.7.2.3. Regulatory Framework
8.7.2.4. Reimbursement Framework
8.7.2.5. Japan Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Target Disease Prevalence
8.7.3.3. Regulatory Framework
8.7.3.4. Reimbursement Framework
8.7.3.5. China Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8. Middle East and Africa
8.8.1. Middle East and Africa Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Target Disease Prevalence
8.8.2.3. Regulatory Framework
8.8.2.4. Reimbursement Framework
8.8.2.5. South Africa Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Target Disease Prevalence
8.8.3.3. Regulatory Framework
8.8.3.4. Reimbursement Framework
8.8.3.5. Saudi Arabia Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Target Disease Prevalence
8.8.4.3. Regulatory Framework
8.8.4.4. Reimbursement Framework
8.8.4.5. UAE Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Target Disease Prevalence
8.8.5.3. Regulatory Framework
8.8.5.4. Reimbursement Framework
8.8.5.5. Kuwait Antidiabetics Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. Novo Nordisk
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Eli Lilly and Company
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Sanofi
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Merck & Co., Inc.
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. AstraZeneca plc
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Johnson & Johnson Services Inc.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Boehringer Ingelheim
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Novartis AG
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Takeda Pharmaceutical Company
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Bayer AG
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of abbreviations
Table 2 Global antidiabetics market, by drug class, 2018-2030 (USD Million)
Table 3 Global antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 4 Global antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 5 Global antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 6 Global antidiabetics market, by region, 2018-2030 (USD Million)
Table 7 North America antidiabetics market, by country, 2018-2030 (USD Million)
Table 8 North America antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 9 North America antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 10 North America antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 11 North America antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 12 U.S. antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 13 U.S. antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 14 U.S. antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 15 U.S. antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 16 Canada antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 17 Canda antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 18 Canada antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 19 Canada antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 20 Mexico antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 21 Mexico antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 22 Mexico antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 23 Mexico antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 24 Europe antidiabetics market, by country, 2018-2030 (USD Million)
Table 25 Europe antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 26 Europe antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 27 Europe antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 28 Europe antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 29 UK antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 30 UK antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 31 UK antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 32 UK antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 33 Germany antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 34 Germany antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 35 Germany antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 36 Germany antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 37 France antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 38 France antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 39 France antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 40 France antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 41 Italy antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 42 Italy antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 43 Italy antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 44 Italy antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 45 Spain antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 46 Spain antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 47 Spain antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 48 Spain antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 49 Denmark antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 50 Denmark antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 51 Denmark antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 52 Denmark antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 53 Sweden antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 54 Sweden antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 55 Sweden antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 56 Sweden antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 57 Norway antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 58 Norway antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 59 Norway antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 60 Norway antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 61 Asia Pacific antidiabetics market, by country, 2018-2030 (USD Million)
Table 62 Asia Pacific antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 63 Asia Pacific antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 64 Asia Pacific antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 65 Asia Pacific antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 66 Japan antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 67 Japan antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 68 Japan antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 69 Japan antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 70 China antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 71 China antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 72 China antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 73 China antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 74 India antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 75 India antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 76 India antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 77 India antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 78 Australia antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 79 Australia antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 80 Australia antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 81 Australia antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 82 Thailand antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 83 Thailand antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 84 Thailand antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 85 Thailand antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 86 South Korea antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 87 South Korea antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 88 South Korea antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 89 South Korea antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 90 Latin America antidiabetics market, by country, 2018-2030 (USD Million)
Table 91 Latin America antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 92 Latin America antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 93 Latin America antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 94 Latin America antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 95 Brazil antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 96 Brazil antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 97 Brazil antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 98 Brazil antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 99 Argentina antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 100 Argentina antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 101 Argentina antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 102 Argentina antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 103 Middle East & Africa antidiabetics market, by country, 2018-2030 (USD Million)
Table 104 Middle East & Africa antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 105 Middle East & Africa antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 106 Middle East & Africa antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 107 Middle East & Africa antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 108 South Africa antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 109 South Africa antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 110 South Africa antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 111 South Africa antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 112 Saudi Arabia antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 113 Saudi Arabia antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 114 Saudi Arabia antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 115 Saudi Arabia antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 116 UAE antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 117 UAE antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 118 UAE antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 119 UAE antidiabetics market, by distribution channel, 2018-2030 (USD Million)
Table 120 Kuwait antidiabetics market, by drug type, 2018-2030 (USD Million)
Table 121 Kuwait antidiabetics market, by diabetes type, 2018-2030 (USD Million)
Table 122 Kuwait antidiabetics market, by route of administration, 2018-2030 (USD Million)
Table 123 Kuwait antidiabetics market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Information procurement
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value chain-based sizing & forecasting
Figure 6 Market formulation & validation
Figure 7 Antidiabetics market segmentation
Figure 8 Market snapshot, 2024
Figure 9 Market trends & outlook
Figure 10 Market driver relevance analysis (current & future impact)
Figure 11 Market restraint relevance analysis (current & future impact)
Figure 12 SWOT analysis, by factor (political & legal, economic, and technological)
Figure 13 Porter’s five forces analysis
Figure 14 Market penetration & growth prospect mapping, 2022
Figure 15 Global antidiabetics market: drug class movement analysis
Figure 16 Global antidiabetics market, for Insulin, 2018-2030 (USD Million)
Figure 17 Global antidiabetics market, for GLP-1 receptor agonists, 2018-2030 (USD Million)
Figure 18 Global antidiabetics market, for DPP- 4 inhibitors, 2018-2030 (USD Million)
Figure 19 Global antidiabetics market, for SGLT2 inhibitors, 2018-2030 (USD Million)
Figure 20 Global antidiabetics market, for others, 2018-2030 (USD Million)
Figure 21 Global antidiabetics market: diabetes type movement analysis
Figure 22 Global antidiabetics market, for type 1, 2018-2030 (USD Million)
Figure 23 Global antidiabetics market, for type 2, 2018-2030 (USD Million)
Figure 24 Global antidiabetics market: route of administration movement analysis
Figure 25 Global antidiabetics market, for oral, 2018-2030 (USD Million)
Figure 26 Global antidiabetics market, for subcutaneous, 2018-2030 (USD Million)
Figure 27 Global antidiabetics market, for intravenous, 2018-2030 (USD Million)
Figure 28 Global antidiabetics market: distribution channel movement analysis
Figure 29 Global antidiabetics market, for online pharmacies, 2018-2030 (USD Million)
Figure 30 Global antidiabetics market, for hospital pharmacies, 2018-2030 (USD Million)
Figure 31 Global antidiabetics market, retail pharmacies, 2018-2030 (USD Million)
Figure 32 Regional marketplace: Key takeaways
Figure 33 Regional outlook, 2024 & 2030
Figure 34 Global antidiabetics market: region movement analysis
Figure 35 North America antidiabetics market, 2018-2030 (USD Million)
Figure 36 U.S. antidiabetics market, 2018-2030 (USD Million)
Figure 37 Canada antidiabetics market, 2018-2030 (USD Million)
Figure 38 Mexico antidiabetics market, 2018-2030 (USD Million)
Figure 39 Europe antidiabetics market, 2018-2030 (USD Million)
Figure 40 Germany antidiabetics market, 2018-2030 (USD Million)
Figure 41 UK antidiabetics market, 2018-2030 (USD Million)
Figure 42 France antidiabetics market, 2018-2030 (USD Million)
Figure 43 Italy antidiabetics market, 2018-2030 (USD Million)
Figure 44 Spain antidiabetics market, 2018-2030 (USD Million)
Figure 45 Denmark antidiabetics market, 2018-2030 (USD Million)
Figure 46 Sweden antidiabetics market, 2018-2030 (USD Million)
Figure 47 Norway antidiabetics market, 2018-2030 (USD Million)
Figure 48 Asia Pacific antidiabetics market, 2018-2030 (USD Million)
Figure 49 Japan antidiabetics market, 2018-2030 (USD Million)
Figure 50 China antidiabetics market, 2018-2030 (USD Million)
Figure 51 India antidiabetics market, 2018-2030 (USD Million)
Figure 52 Australia antidiabetics market, 2018-2030 (USD Million)
Figure 53 South Korea antidiabetics market, 2018-2030 (USD Million)
Figure 54 Thailand antidiabetics market, 2018-2030 (USD Million)
Figure 55 Latin America antidiabetics market, 2018-2030 (USD Million)
Figure 56 Brazil antidiabetics market, 2018-2030 (USD Million)
Figure 57 Argentina antidiabetics market, 2018-2030 (USD Million)
Figure 58 Middle East and Africa antidiabetics market, 2018-2030 (USD Million)
Figure 59 South Africa antidiabetics market, 2018-2030 (USD Million)
Figure 60 Saudi Arabia antidiabetics market, 2018-2030 (USD Million)
Figure 61 UAE antidiabetics market, 2018-2030 (USD Million)
Figure 62 Kuwait antidiabetics market, 2018-2030 (USD Million)

Companies Mentioned

The companies profiled in this Antidiabetics market report include:
  • Novo Nordisk
  • Eli Lilly and Company
  • Sanofi
  • Merck & Co., Inc.
  • AstraZeneca plc
  • Johnson & Johnson Services Inc.
  • Boehringer Ingelheim
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Bayer AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 91.34 Billion
Forecasted Market Value ( USD ) by 2030 $ 168.55 Billion
Compound Annual Growth Rate10.7%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Distribution Channel, Therapy Type, End User - Global Forecast to 2030 - Product Image

Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Distribution Channel, Therapy Type, End User - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

Antidiabetics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 183 Pages
  • Global
From
Antidiabetics Market Report 2025 - Product Image

Antidiabetics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Antidiabetics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Antidiabetics Drug Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 86 Pages
  • Global
From
Oral Antidiabetic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034 - Product Image

Oral Antidiabetic Drugs Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025-2034

  • Report
  • 145 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.